FIGURE 1

Total Splenocyte Counts



Total splenocyte count performed by trypan blue exclusion on male Balb/c mice after 6 days (n=3) or 30 days (n=8) of treatment in vivo with CPDS.
* statistically significant

FIGURE 2

NK cell activity



NK cell activity of male Balb/c mice, expressed as a percentage of specific lysis for an effector:target (E:T) ratio of 200:1, after 6 days (n=3) or 30 days (n=8) of *in vivo* treatment with CPDS.

* statistically significant

FIGURE 3

Immunophenotyping



Spleen cell subset of male Balb/c mice, after 6 days of treatment *in vivo* with CPDS, expressed as percentage of total population. Cells were labeled with fluorescent antibodies and labeling was analyzed by flow cytometry (n=3).

FIGURE 4

Immunophenotyping



Spleen cell subset of male Balb/c mice, after 30 days of treatment *in vivo* with CPDS, expressed as percentage of total population. Cells were labeled with fluorescent antibodies and labeling was analyzed by flow cytometry (n=8).

* statistically significant

FIGURE 5

Mitogenic proliferation



Proliferation (cpm) of splenocytes from Balb/c males following exposure to different mitogens: phytohemagglutinin (PHA), concanavalin A (CON A) and lipopolysaccharide (LPS). Animal (n=3) were treated or not with CPDS for 6 days.

FIGURE 6

Mitogenic Proliferation



Proliferation (cpm) of splenocytes from Balb/c males following exposure to different mitogens: phytohemagglutinin (PHA), concanavalin A (CON A) and Lipopolysaccharide (LPS). Animal (n=8) were treated or not with CPDS for 30 days.

* statistically significant

FIGURE 7

Humoral response to KLH Immunization



Keyhole limpet hemocyanine (KLH) antibodies quantification in serum of male Balb/C mice following *in vivo* treatment with CPDS for 45 days. Antibody titers were determined by dot blot and converted $\log_2$ of the dilution.

* statistically significant